{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:03:48Z","timestamp":1779944628252,"version":"3.53.1"},"reference-count":44,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the treatment of type 2 diabetes (T2D), are increasingly used for the management of overweight and obesity in children and adolescents. However, the impact of concomitant lifestyle interventions, which vary in scope, structure, and intensity, remains unclear. Methods: A systematic search of PubMed, Scopus, and ClinicalTrials.gov was conducted from April to December 2025 (last update: 12 December 2025), in accordance with the PRISMA 2020 statement. Randomized and observational studies including patients aged 6\u201319 years with overweight or obesity, with or without T2D, treated with GLP-1 RAs or dual GIP\/GLP-1 agonists, were included. Anthropometric outcomes, metabolic parameters, and the scope and structure of concomitant nutritional and behavioral interventions were assessed. Results: Fifteen studies (12 interventional [RCT\/non-RCT] and 3 observational), including 1448 participants, were analyzed: liraglutide (n = 6), exenatide (n = 5), semaglutide (n = 1), dulaglutide (n = 1), tirzepatide (n = 1), and lixisenatide (n = 1). Intervention duration ranged from 6 to 68 weeks. Reported BMI reductions varied across studies and pharmacological agents, with semaglutide trials reporting reductions of up to \u221216.1%. Lifestyle interventions were heterogeneously reported, ranging from general dietary advice to structured, multidisciplinary programs including nutritional counseling, physical activity, and behavioral or family support. Due to heterogeneity in study design and reporting, the independent contribution of lifestyle interventions could not be determined. Conclusions: Available evidence suggests that GLP-1 RAs may represent an effective therapeutic option for children and adolescents with obesity and metabolic disorders. However, available evidence is largely derived from studies incorporating inconsistently reported lifestyle interventions, limiting the ability to disentangle pharmacological and lifestyle effects. Standardized reporting and studies specifically designed to assess their independent and combined effects are needed. Future research should standardize the reporting of lifestyle protocols (e.g., using TIDieR), incorporate validated measures of eating behavior, food preferences, and dietary intake, and use designs (e.g., factorial or stratified randomization of lifestyle intensity) that allow for the pharmacological and behavioral contributions to be quantified separately. This review highlights a critical and previously underexplored methodological gap regarding the structure and reporting of lifestyle co-interventions in pediatric GLP-1 trials.<\/jats:p>","DOI":"10.3390\/nu18111662","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:14:52Z","timestamp":1779452092000},"page":"1662","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists and Dual GIP\/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions\u2014A Systematic Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2331-4106","authenticated-orcid":false,"given":"Dominika","family":"My\u015bliwczyk","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gda\u0144sk, Marii Sk\u0142odowskiej-Curie 3a, 80-210 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof Ksawery","family":"Gofron","sequence":"additional","affiliation":[{"name":"Student Scientific Circle at Department of Clinical Nutrition, Medical University of Gda\u0144sk, Marii Sk\u0142odowskiej-Curie 3a, 80-210 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-6921","authenticated-orcid":false,"given":"Andrzej","family":"Wasilewski","sequence":"additional","affiliation":[{"name":"Student Scientific Association of Medical Chemistry and Immunochemistry, Wroclaw Medical University, Marii Sk\u0142odowskiej-Curie 48\/50, 59-369 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1533-8544","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"My\u015bliwiec","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gda\u0144sk, Marii Sk\u0142odowskiej-Curie 3a, 80-210 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5288-0586","authenticated-orcid":false,"given":"Eliza","family":"Wasilewska","sequence":"additional","affiliation":[{"name":"Department of Allergology, Medical University of Gda\u0144sk, Marii Sk\u0142odowskiej-Curie 3a, 80-210 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, November 15). Obesity and Overweight. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref_2","unstructured":"World Health Organization (2020). Spotlight on Adolescent Health and Well-Being: Findings from the 2017\/2018 Health Behaviour in School-Aged Children (HBSC) Survey in Europe and Canada, World Health Organization."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/obr.12334","article-title":"Predicting Adult Obesity from Childhood Obesity: A Systematic Review and Meta-analysis","volume":"17","author":"Simmonds","year":"2016","journal-title":"Obes. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jama.2021.11165","article-title":"Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001\u20132017","volume":"326","author":"Lawrence","year":"2021","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The Physiology of Glucagon-like Peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (2026, April 10). SAXENDA (Liraglutide) Injection, for Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/206321s016lbl.pdf."},{"key":"ref_10","unstructured":"European Medicines Agency (2026, April 10). Saxenda. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/epar\/saxenda."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2026, April 10). VICTOZA (Liraglutide) Injection, for Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022341orig1s042lbl.pdf."},{"key":"ref_12","unstructured":"European Medicines Agency (2026, April 10). Victoza. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/epar\/victoza."},{"key":"ref_13","unstructured":"U.S. Food and Drug Administration (2026, April 10). WEGOVY (Semaglutide) Injection, for Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf."},{"key":"ref_14","unstructured":"European Medicines Agency (2026, April 10). Wegovy. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/epar\/wegovy."},{"key":"ref_15","unstructured":"U.S. Food and Drug Administration (2026, April 10). TRULICITY (Dulaglutide) Injection, for Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125469orig1s000approv.pdf."},{"key":"ref_16","unstructured":"European Medicines Agency (2026, April 10). Trulicity. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/epar\/trulicity."},{"key":"ref_17","unstructured":"European Medicines Agency (2026, April 10). Bydureon. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/epar\/bydureon."},{"key":"ref_18","unstructured":"U.S. Food and Drug Administration (2026, April 10). MOUNJARO (Tirzepatide) Injection, for Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf."},{"key":"ref_19","unstructured":"European Medicines Agency (2026, April 10). Mounjaro, INN-Tirzepatide. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mounjaro-epar-product-information_en.pdf."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (2026, April 10). ZEPBOUND (Tirzepatide) Injection, for Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209210s025lbl.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (Robvis): An R Package and Shiny Web App for Visualizing Risk-of-bias Assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(25)01774-X","article-title":"Efficacy and Safety of Tirzepatide in Children and Adolescents with Type 2 Diabetes (SURPASS-PEDS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"406","author":"Hannon","year":"2025","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/pedi.13343","article-title":"A Study on Pharmacokinetics, Pharmacodynamics and Safety of Lixisenatide in Children and Adolescents with Type 2 Diabetes","volume":"23","author":"Hsia","year":"2022","journal-title":"Pediatr. Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-Weekly Semaglutide in Adolescents with Obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e12624","DOI":"10.1111\/ijpo.12624","article-title":"A 6-month Randomized, Double-blind, Placebo-controlled Trial of Weekly Exenatide in Adolescents with Obesity","volume":"15","author":"Weghuber","year":"2020","journal-title":"Pediatr. Obes."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamapediatrics.2013.1045","article-title":"The Effect of Glucagon-like Peptide-1 Receptor Agonist Therapy on Body Mass Index in Adolescents with Severe Obesity","volume":"167","author":"Kelly","year":"2013","journal-title":"JAMA Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2337\/dc21-2275","article-title":"Once-Weekly Exenatide in Youth with Type 2 Diabetes","volume":"45","author":"Tamborlane","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/oby.23395","article-title":"Exenatide for Weight-loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-controlled Trial","volume":"30","author":"Fox","year":"2022","journal-title":"Obesity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/oby.2011.337","article-title":"Exenatide as a Weight-Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study","volume":"20","author":"Kelly","year":"2012","journal-title":"Obesity"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in Children and Adolescents with Type 2 Diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa2407379","article-title":"Liraglutide for Children 6 to <12 Years of Age with Obesity\u2014A Randomized Trial","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_35","first-page":"e58720","article-title":"Single-Center Experience of Using Liraglutide in Adolescents With Obesity +\/\u2212 Type 2 Diabetes","volume":"16","author":"Dauleh","year":"2024","journal-title":"Cureus"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cominato, L., Resende, M.L., Bernardes, N., Rachid, L.L., Passone, C.G.B., Mattar, L.B.F., Neme, G., Souza, S.G., Santos, C.R.P., and Franco, R.R. (2025). 12-Month Outcomes of GLP-1 in Severe Pediatric Obesity: Real-World Data. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1663499"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"503856","DOI":"10.1016\/j.anpedi.2025.503856","article-title":"Efectividad de La Liraglutida En El Tratamiento de La Obesidad Del Adolescente","volume":"103","author":"Pons","year":"2025","journal-title":"An. Pediatr. (Engl. Ed.)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e70077","DOI":"10.1111\/obr.70077","article-title":"A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide","volume":"27","author":"Jansson","year":"2026","journal-title":"Obes. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1037\/0278-6133.13.5.373","article-title":"Ten-Year Outcomes of Behavioral Family-Based Treatment for Childhood Obesity","volume":"13","author":"Epstein","year":"1994","journal-title":"Health Psychol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1037\/amp0000293","article-title":"Behavioral Interventions for Obesity in Children and Adults: Evidence Base, Novel Approaches, and Translation into Practice","volume":"73","author":"Wilfley","year":"2018","journal-title":"Am. Psychol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans","volume":"63","author":"IJzerman","year":"2014","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2017.01.025","article-title":"Gut-Brain Cross-Talk in Metabolic Control","volume":"168","author":"Clemmensen","year":"2017","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The Effect of Semaglutide 2.4 Mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults with Obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gofron, K.K., Wasilewski, A., and Ma\u0142gorzewicz, S. (2025). Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients, 17.","DOI":"10.3390\/nu17081303"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/11\/1662\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:16:38Z","timestamp":1779941798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/11\/1662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["nu18111662"],"URL":"https:\/\/doi.org\/10.3390\/nu18111662","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}